Core Viewpoint - Revelation Biosciences, Inc. has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 13,065,000 shares of common stock at a reduced exercise price of $0.86 per share [1]. Group 1 - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1]. - The existing warrants were issued on September 11, 2025 [1]. - The shares of common stock that can be issued upon exercise of the existing warrants are registered under an effective registration statement on Form S-3 [1].

Core Viewpoint - Revelation Biosciences, Inc. has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025, indicating strong shareholder engagement [1] Company Summary - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1] - Shareholders are reminded that voting is open until 11:59pm ET on December 2, 2025 [1]

Core Points - Revelation Biosciences, Inc. has adjourned its 2025 Special Meeting of Stockholders due to insufficient shares present for voting [1] - The Special Meeting was originally scheduled for October 15, 2025, and will now reconvene on October 29, 2025, at 12:00 p.m. [1] Company Summary - Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation [1]

Core Insights - Revelation Biosciences, Inc. has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 4,355,000 shares of common stock at an exercise price of $2.20 per share [1] Company Summary - The company is a clinical-stage life sciences firm focused on rebalancing inflammation [1] - The existing warrants were issued on May 29, 2025, and the shares are registered under an effective registration statement on Form S-1 [1]